Dana-Farber Cancer Institute, Inc. v. Ono Pharmaceutical Co.

 
APPEAL NO.
19-2050
OP. BELOW
DCT
SUBJECT
Patent
AUTHOR
Lourie

Question(s) Presented

  1. “Whether the panel erred in adopting a bright-line rule that the novelty and non-obviousness of an invention over alleged contributions to conception are ‘not probative’ of whether those alleged contributions were significant to conception.”
  2. “Whether the panel erred in holding that alleged contributions to the conception of an invention can be ‘significant’ even though the content of the alleged contributions was publicly disclosed before the date of conception.”

Posts About this Case